Search clinical trials for: 5 mg empagliflozin

Total 17249 results

University of Pisa

Unknown

Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy (PURITY)

Glucose Metabolism Disorders | Renal Function Disorder

Italy
Aristotle University Of Thessaloniki

Unknown

Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics (PREHYPD)

Hypertension | Type II Diabetes

Greece
Ain Shams University

Completed

Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin

Pharmacokinetics | Pharmacogenomic

Egypt
Yaounde Central Hospital

Completed

Short Term Effect of Empagliflozin in Hypertension (EMPHYT)

Hypertension

Cameroon
Boehringer Ingelheim

Completed

Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together

Healthy

Germany
Centre Hospitalier Universitaire Dijon

Completed

Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes (Cinétique DAPA)

Type-2 Diabetes | Oral Antidiabetics

France
Pfizer

Completed

A Study Of CP-690,550 In Stable Kidney Transplant Patients

Kidney Transplant

United States
Columbia University
University of Minnesota

Terminated

Intralesional Steroids in the Treatment of Alopecia Areata

Alopecia Areata

United States
Organon and Co

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)

Schizophrenia | Bipolar I Disorder
Eisai Co., Ltd.

Completed

A Single-dose Study in Healthy Japanese Male Adults to Evaluate Pharmacokinetics and Pharmacodynamics of E5501 5 mg Tablet (Study E5501-J081-015)

Healthy

Japan
Oslo University Hospital

Completed

Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD) (Z-AMD)

Neovascular Age-related Macular Degeneration

Norway
The Deutsche Diabetes Forschungsgesellschaft e.V.
Novo Nordisk A/S; Boehringer Ingelheim; Federal Ministry of Health, Germany; German... and other collaborators

Recruiting

Combined Active Treatment in Type 2 Diabetes With NASH (COMBAT_T2_NASH)

Type 2 Diabetes | Non-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)

Germany, Austria
University of Pisa

Completed

Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.

Type2 Diabetes Mellitus

Italy
University of Utah

Active, not recruiting

5-HTP and Creatine for Depression

Major Depressive Disorder

United States
Boehringer Ingelheim

Recruiting

Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure

Heart Failure

Korea, Republic of
Jeil Pharmaceutical Co., Ltd.

Completed

Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects

Anti-Ulcer Agents

Korea, Republic of
Amsterdam UMC, location VUmc

Withdrawn

REGROUP: Renohemodynamic Effects empaGliflozin in vaRiOUs Populations (REGROUP)

Diabetes Mellitus, Type 2 | Chronic Kidney Diseases
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

Healthy

Germany
Menarini Group

Completed

A Locally Injected Bradykinin Antagonist for TReatment of OSteoarthritiS (ALBATROSS)

Osteoarthritis, Knee

Germany, France, Italy, Spain
Novartis

Completed

Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

Essential Hypertension

Japan
University Hospital, Basel, Switzerland
Boehringer Ingelheim

Recruiting

Empagliflozin for the Treatment of Postprandial Hypoglycemia (EmpHy)

Postprandial Hypoglycemia

Switzerland
Boehringer Ingelheim

Withdrawn

Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas

Cardiovascular Diseases | Diabetes Mellitus, Type 2

United States
Assistance Publique Hopitaux De Marseille

Completed

Impact of Empaglifozine on Cardiac Ectopic Fat (EMPACEF)

Type 2 Diabetes

France
Oslo University Hospital
Vestre VikenHF Kongsberg Sykehus

Recruiting

Affective Effects of Pre-surgery Opioids: a Randomized, Doubleblind Placebo-controlled Trial (AFFECT2)

Opioid Use | Affective Symptoms

Norway
Daewoong Pharmaceutical Co. LTD.

Active, not recruiting

The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin

Glucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Metabolic Disease

China
Merck Sharp & Dohme LLC

Terminated

A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005

Solid Tumors
Aziende Chimiche Riunite Angelini Francesco S.p.A
Cross S.A.

Completed

New Paediatric Formulation of Tachipirina®

Healthy

Switzerland
GlaxoSmithKline
Zensei Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study Between Levocetirizine Oral Disintegrating Tablet (ODT) and Levocetirizine Immediate Release Tablet (IRT)

Rhinitis

Japan
Universiti Sains Malaysia

Completed

The Effects of Tualang Honey on Postmenopausal Women

Postmenopausal Syndrome

Malaysia
CymaBay Therapeutics, Inc.

Completed

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary Biliary Cholangitis

United States, Spain, France, Korea, Republic of, Denmark, Australia, Italy, United Kingdom, Belgium, Canada, Russian Federation, Romania, Germany, Hungary, Mexico, Turkey, Argentina, Austria, Chile, Czechia, Greece, Israel, New Zealand and more
Bronx VA Medical Center

Completed

Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)

Hypercholesterolemia

United States
William Sikov MD
The Miriam Hospital; Rhode Island Hospital; Memorial Hospital of Rhode Island

Completed

Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)

Rectal Cancer | Colon Cancer

United States
Yuyu Pharma, Inc.

Completed

Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil

Benign Prostatic Hyperplasia

Korea, Republic of
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg

Healthy

United States
University Hospital Tuebingen

Completed

Effect of Empagliflozin Versus Placebo on Brain Insulin Sensitivity in Patients With Prediabetes

Body Weight | PreDiabetes

Germany
AstraZeneca

Completed

The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

Type 1 Diabetes Mellitus

Japan
University Hospital, Gentofte, Copenhagen

Completed

Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon Secretion (Px-Meal)

Diabetes After Total Pancreatectomy

Denmark
Intercept Pharmaceuticals
Syneos Health; Global PBC Study Group; Target RWE; UK PBC Study Group

Withdrawn

A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients (HEROES-PBC)

Primary Biliary Cholangitis

United States
Yuhan Corporation

Not yet recruiting

Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension

Essential Hypertension

Korea, Republic of
Astellas Pharma Europe Ltd.

Completed

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (BESIDE)

Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
Royal Perth Hospital

Recruiting

Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans (EMPA-SNS)

Obesity | Type 2 Diabetes Mellitus | Metabolic Syndrome

Australia
Dong Wha Pharmaceutical Co. Ltd.

Completed

This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component(Empagliflozin and Metformin) in Healthy Adult Volunteers in Fast Condition.

Healthy Subjects

Korea, Republic of
Samuel Lunenfeld Research Institute, Mount Sinai...
McGill University Health Centre/Research Institute of the McGill University...

Completed

Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting (CLASS17)

Type1 Diabetes Mellitus

Canada
CymaBay Therapeutics, Inc.

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Primary Biliary Cirrhosis

United States, Korea, Republic of, Belgium, Spain, France, Switzerland, Romania, United Kingdom, Austria, Israel, Australia, Argentina, Canada, Chile, Germany, Greece, Hungary, Italy, Mexico, Netherlands, Poland, Czechia, New Zealand, Turke... and more
Intercept Pharmaceuticals
Syneos Health; Global PBC Study Group; Target RWE; UK PBC Group

Completed

Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients (HEROES PBC)

Primary Biliary Cholangitis

United States
CymaBay Therapeutics, Inc.

Completed

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary Biliary Cholangitis

United States, Spain, United Kingdom, Israel, France, Korea, Republic of, Australia, Italy, Hungary, Germany, Romania, Belgium, Canada, Greece, New Zealand, Austria, Serbia, Russian Federation, Argentina, Mexico, Netherlands, Chile, Polan...
AstraZeneca

Completed

Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants

Chronic Kidney Disease

United States
Mylan Pharmaceuticals Inc

Completed

Fed Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg

Healthy

United States
AstraZeneca

Completed

Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

Type 2 Diabetes Mellitus

China

Search clinical trials for: 5 mg empagliflozin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations